Phase I Clinical Trial Evaluating the Safety and Response With PF-05082566, Cetuximab and Irinotecan in Patients With Advanced Colorectal Cancer

Trial Profile

Phase I Clinical Trial Evaluating the Safety and Response With PF-05082566, Cetuximab and Irinotecan in Patients With Advanced Colorectal Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Jan 2018

At a glance

  • Drugs Cetuximab (Primary) ; Irinotecan (Primary) ; Utomilumab (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 27 Dec 2017 Planned End Date changed from 1 Feb 2022 to 1 Dec 2021.
    • 27 Dec 2017 Planned primary completion date changed from 1 Feb 2022 to 1 Dec 2021.
    • 27 Dec 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top